Skip to main content
Premium Trial:

Request an Annual Quote

Axxam Receives Two Grants Worth 7.8M Euro from Italian Government

NEW YORK, Jan. 10 (GenomeWeb News) - Axxam said today that it has received two research grants, worth a total of €7.8 million, from the Italian Research Ministry and the Regione Lombardia to advance drug-discovery projects.


The first grant, worth €6.7 million, will be awarded over a three-year period with 33 percent non-refundable and 67 percent repayable at a 0.5 percent interest rate within ten years time. The funding was granted in support of Axxam's development of advanced screening assays for high-throughput screening, as well as new screening technologies, the company said.


The second grant, worth €1.1 million, will be awarded over two years and is non-refundable, said Axxam. The financing will support a new project in the field of cell-based assays for HTS based on the innovative use of mouse stem cells.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.